cept Therapeutics rporated-One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit

One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit

247Wallst·2026-01-15 19:47

Corcept Therapeutics (NASDAQ: CORT) and Amicus Therapeutics (NASDAQ: FOLD) delivered Q3 2025 results highlighting two rare disease biotechs at opposite ends of the profitability spectrum. ...